A Phase 2 interventional study of [13N]NH3 and Lexiscan in Sickle Cell Disease, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital — 15 open to participants now, 17 under way, none of them phase 3. Anemia, Sickle Cell · St. Jude Children's Research Hospital.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, this one is the 13th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2023, is one of 10 in phase 2, reaches primary completion later than 7 of the 16 other live ones, and was the 35th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →15 of the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in Mozambique
Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
St. Jude Children's Research Hospital · Sites in United States
Ages 10–18 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 8–17
St. Jude Children's Research Hospital · Sites in United States
Ages 42 mo–78 mo
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 21 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 45 across the 22 interventional studies, 88 across the 23 observational. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
4 of the studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03353584St. Jude Children's Research HospitalEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease | 2026-11 |
| NCT06477289St. Jude Children's Research HospitalPeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease | 2027-06 |
| NCT07226219St. Jude Children's Research HospitalMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | 2027-07-01 |
| NCT05583721St. Jude Children's Research HospitalRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is limited information on what causes injury to the heart in individuals with Sickle Cell Disease (SCD). Researchers in this study want to see if decreased blood flow to the heart during stress could be causing the heart damage seen in SCD patients. They also want to test people who don't have SCD to see if their hearts react the same way under stress.
Primary Objective
Secondary Objectives
This study requires two visits. The first visit includes blood tests, an electrocardiogram (EKG), and an echocardiogram. The second visit includes a positron emission tomography (PET) stress test and a blood test.
Subjects will be considered off-study one week after all post PET imaging study tests have been completed along with the next day and one-week follow-up phone calls are completed.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Inclusion Criteria - Stratum A: Sickle cell patients with diastolic dysfunction
Inclusion Criteria - Stratum B: Sickle cell patients without diastolic dysfunction
Inclusion Criteria - Stratum C: Healthy controls
Exclusion Criteria - Stratum A:
Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised.
Exclusion Criteria - Stratum B:
Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised.
Exclusion Criteria - Stratum C:
Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sickle Cell patients with diastolic dysfunction
Drug: [13N]NH3 · Drug: Lexiscan · Diagnostic Test: Positron emission tomography
Sickle cell patients without diastolic dysfunction
Drug: [13N]NH3 · Drug: Lexiscan · Diagnostic Test: Positron emission tomography
Healthy controls
Drug: [13N]NH3 · Drug: Lexiscan · Diagnostic Test: Positron emission tomography
Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
Also known as: [N-13] Ammonia, azane, CAS# 34819-78-8
Given IV prior to PET stress test
Also known as: Regadenoson
Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
Also known as: PET
Mean and standard deviation of coronary flow reserve (CFR)
We will estimate the mean and standard deviation of CFR, as measured by PET myocardial blood flow reserve imaging, in young adult SCD patients with and without diastolic dysfunction and healthy controls.
Time frame: Visit 2, approximately 4 weeks after study entry (procedure takes approximately one hour)
CFR difference among Stratum A, Stratum B, and Stratum C
We will compare whether the CFR is different among 3 predefined strata: Stratum A; SCD with diastolic dysfunction patients , Stratum B; SCD without dysfunction patient control, and Stratum C; normal healthy controls by one-way ANOVA or Kruskal-Wallis one-way analysis of variance, depending on the distribution of the data. If the difference exists, the pairwise comparison will be carried out by two sample t test or Wilcoxon rank sum test between two strata.
Time frame: Visit 2, approximately 4 weeks after study entry (procedure takes approximately one hour)
Relationship between decreased CFR (quantified with PET stress-rest myocardial perfusion imaging) and presence of abnormal diastolic parameters
The following is the grouping of diastolic parameters used in this study: Group 1: 0 or any 1 diastolic variable abnormal; Group 2: Any 2 variables abnormal; Group 3: Any 3 or more variables abnormal . We will first summarize the mean and standard deviation CFR values for each diastolic group. One-way ANOVA or Kruskal-Wallis one-way ANOVA will be used to explore whether there are any statistically significant differences between the means of these three groups. If a difference exists, the pairwise comparison will be carried out by two sample t test or Wilcoxon rank sum test between two groups.
Time frame: Visit 2, approximately 4 weeks after study entry (procedure takes approximately one hour)
Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available at the time of article publication.
Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.
Started Oct 2023 (actual). Primary completion is estimated for Sep 2027, 47 months after the start.
Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 47 months is below that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Jude Children's Research Hospital →